Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer

[1]  M. Bogyo,et al.  Activity-based profiling of proteases. , 2014, Annual review of biochemistry.

[2]  M. Fonović,et al.  Cysteine cathepsins and their potential in clinical therapy and biomarker discovery , 2014, Proteomics. Clinical applications.

[3]  Robin L. Jones,et al.  Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. , 2014, Cell reports.

[4]  L. O. Mosnier,et al.  Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. , 2013, Blood.

[5]  A. Richardson,et al.  Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. , 2012, Cancer discovery.

[6]  G. Caliendo,et al.  Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. , 2012, Journal of medicinal chemistry.

[7]  M. Juliano,et al.  Baupain, a plant cysteine proteinase that hinders thrombin-induced human platelet aggregation. , 2012, Protein and peptide letters.

[8]  R. Samant,et al.  The Hedgehog Pathway Conditions the Bone Microenvironment for Osteolytic Metastasis of Breast Cancer , 2011, International journal of breast cancer.

[9]  Olga Vasiljeva,et al.  Cysteine cathepsins: From structure, function and regulation to new frontiers☆ , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.

[10]  E. De Candia.  Mechanisms of platelet activation by thrombin: a short history. , 2012, Thrombosis research.

[11]  M. Bogyo,et al.  Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. , 2011, Gastroenterology.

[12]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[13]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[14]  M. Platt,et al.  Multiplex Zymography Captures Stage-specific Activity Profiles of Cathepsins K, L, and S in Human Breast, Lung, and Cervical Cancer , 2011, Journal of Translational Medicine.

[15]  Z. Salah,et al.  PAR1 plays a role in epithelial malignancies: Transcriptional regulation and novel signaling pathway , 2011, IUBMB life.

[16]  P. Clézardin.  Therapeutic targets for bone metastases in breast cancer , 2011, Breast Cancer Research.

[17]  H. Hamm,et al.  Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A2&agr; Differently for Cyclooxygenase-1 and 12-Lipoxygenase Catalysis , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[19]  H. Versteeg,et al.  Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. , 2010, Blood.

[20]  R. Samant,et al.  Hedgehog Signaling Induced by Breast Cancer Cells Promotes Osteoclastogenesis and Osteolysis* , 2010, The Journal of Biological Chemistry.

[21]  A. Jensen,et al.  The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. , 2010, Clinical breast cancer.

[22]  T. Reinheckel,et al.  Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.

[23]  E. Lerner,et al.  Plant cysteine proteases that evoke itch activate protease‐activated receptors , 2010, The British journal of dermatology.

[24]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. LaMotte,et al.  Cathepsin S elicits itch and signals via protease-activated receptors. , 2010, The Journal of investigative dermatology.

[26]  A. Poole,et al.  Protein Kinase Cθ Negatively Regulates Store-independent Ca2+ Entry and Phosphatidylserine Exposure Downstream of Glycoprotein VI in Platelets* , 2010, The Journal of Biological Chemistry.

[27]  D. Wagner,et al.  p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. , 2010, Blood.

[28]  Bonnie F. Sloane,et al.  Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. , 2009, The American journal of pathology.

[29]  D. Brömme,et al.  Cathepsin K inhibitors for osteoporosis and potential off-target effects , 2009, Expert opinion on investigational drugs.

[30]  M. Hollenberg,et al.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.

[31]  D. Brömme,et al.  Biochemical properties and regulation of cathepsin K activity. , 2008, Biochimie.

[32]  K. Brix,et al.  Cysteine cathepsins: cellular roadmap to different functions. , 2008, Biochimie.

[33]  D. Wink,et al.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. , 2008, Blood.

[34]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[35]  A. Malik,et al.  Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization , 2007, Proceedings of the National Academy of Sciences.

[36]  M. Rojas,et al.  Src family kinases mediate neutrophil adhesion to adherent platelets. , 2007, Blood.

[37]  M. Bryckaert,et al.  Protease-activating Receptor-4 Induces Full Platelet Spreading on a Fibrinogen Matrix , 2007, Journal of Biological Chemistry.

[38]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[39]  T. Luger,et al.  Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. , 2006, Cancer research.

[40]  P. Jurasz,et al.  Platelet Aggregation-Induced by Caco-2 Cells: Regulation by Matrix Metalloproteinase-2 and Adenosine Diphosphate , 2006, Journal of Pharmacology and Experimental Therapeutics.

[41]  M. Blaber,et al.  Substrate Specificity of Human Kallikrein 6 , 2006, Journal of Biological Chemistry.

[42]  K. Brix,et al.  Watching proteases in action , 2005, Nature chemical biology.

[43]  C. Esmon,et al.  PAR1 Cleavage and Signaling in Response to Activated Protein C and Thrombin* , 2005, Journal of Biological Chemistry.

[44]  D. Gnatenko,et al.  Expression of protease activated receptor 3 (PAR3) is upregulated by induction of megakaryocyte phenotype in human erythroleukemia (HEL) cells. , 2004, Experimental hematology.

[45]  P. Hogendoorn,et al.  Cathepsin K is the principal protease in giant cell tumor of bone. , 2004, The American journal of pathology.

[46]  L. Juliano,et al.  Cathepsin B Activity Regulation , 2001, The Journal of Biological Chemistry.

[47]  S. Coughlin,et al.  PAR3 is a cofactor for PAR4 activation by thrombin , 2000, Nature.

[48]  L. Juliano,et al.  Cathepsin B Activity Regulation HEPARIN-LIKE GLYCOSAMINOGLYCANS PROTECT HUMAN CATHEPSIN B FROM ALKALINE pH-INDUCED INACTIVATION* , 2000 .

[49]  L. Juliano,et al.  Specificity of Cathepsin B to Fluorescent Substrates Containing Benzyl Side-Chain-Substituted Amino Acids at P1 Subsite , 2000, Journal of protein chemistry.

[50]  E. Mehler,et al.  Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. , 1999, Biochemistry.

[51]  Robert V Farese,et al.  A dual thrombin receptor system for platelet activation , 1998, Nature.

[52]  D. Maglott,et al.  The Human Proteinase-activated Receptor-3 (PAR-3) Gene , 1998, The Journal of Biological Chemistry.

[53]  S. Coughlin,et al.  Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. , 1998, Blood.

[54]  M. Heath,et al.  Cloning of PAR3 cDNA from human platelets, and human erythroleukemic and human promonocytic cell lines. , 1997, Blood.

[55]  S. Coughlin,et al.  The Cloned Thrombin Receptor Is Necessary and Sufficient for Activation of Mitogen-activated Protein Kinase and Mitogenesis in Mouse Lung Fibroblasts , 1996, The Journal of Biological Chemistry.

[56]  R. Smith,et al.  Potent inactivation of cathepsins S and L by peptidyl (acyloxy)methyl ketones. , 1994, Biological chemistry Hoppe-Seyler.

[57]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[58]  Bonnie F. Sloane,et al.  Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. , 1982, Science.